Patent SG-11201901762W-A (SG)
Title: Methods and composition for the prediction of the activity of enzastaurin
Inventor: LUO WEN
IPC: C12Q1/68
Filed: 2017-08-31
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/045240 Al 08 March 2018 (08.03.2018) W I PO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: (74) Agent: YIN, Bu et al.; Morrison & Foerster LLP, 12531 C12Q 1/68 (2006.01) High Bluff Drive, Suite 100, San Diego, CA 92130-2040 International Application Number: (US). PCT/US2017/049747 (81) Designated States (unless otherwise indicated, for every International Filing Date: kind of national protection available): AE, AG, AL, AM, 31 August 2017 (31.08.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/382,734 01 September 2016 (01.09.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/414,601 28 October 2016 (28.10.2016) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: DENOVO BIOPHARMA LLC [US/US]; 6331 Nancy Ridge Drive, San Diego, CA 92121 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, Inventors: LUO, Wen; c/o Denovo Biopharma LLC, 6331 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Nancy Ridge Drive, San Diego, CA 92121 (US). SUN, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Hong; c/o Denovo Biopharma LLC, 6331 Nancy Ridge Dri-TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, ye, San Diego, CA 92121 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = Title: METHODS AND Overall Survival in Enza + RCHOP Treated Patients Carrying Different .100 90 1 so 70 ? 60 Tri > > I- OD 40 30 20 10 (54) COMPOSITION FOR THE PREDICTION OF THE ACTIVITY OF ENZASTAURIN Figure 3C. S028 First Line Genotypes = = = = _ = = — = i , , I -6- R-CHOPIEnza AA+AB (N=48) * - R-CHOP/Enza BB (N=9) 1 1 1 1 -, AA+AB vs. BB in R-CHOP/Enza Hazard ratio (95% CI): 0.096 (0.019, 0.492) p.0.005 = — = = = _ = 1-1 .4 © N kin ii- c:::: , (57) --- -- GC (e.g., ,-1 The 0 can N by 71- 10 20 30 40 50 60 70 80 Months : The present invention describes biomarkers that have been discovered to correlate with varied individual responses efficacy, adverse effect, and other end points) to enzastaurin, in treating diseases such as, DLBCL, GBM, and other cancer types. newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might not be beneficial, the treatment. [Continued on next page] WO 2018/045240 Al MIDEDIMOMMIDIREEMOMIVEIDEMOIHMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of earlier application (Rule 4.17(iii)) he Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))